The tweet was deleted by the author.
But we saved everything 🙂.
Eyepoint Pharmaceuticals released its financial results for the second quarter of 2026, revealing key figures and strategic corporate developments.
The pharmaceutical company used this update to inform investors of recent advancements and changes within its organization. Specific financial data and additional details can be found through the provided link. Details are being clarified.
View post on X Loading...
Eyepoint Pharmaceuticals recently named Tarek S Hassan as chief strategic science officer ahead of anticipated Phase 3 results for wet AMD, according to a prior announcement. The company has also completed Phase 3 enrollment for DURAVYU in DME trials, with topline data expected in late 2027, as detailed in another recent update. These initiatives follow the company’s ongoing strategy to advance its clinical pipeline.